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Abstract
Nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale and warrants urgent
investigation of its therapeutic potential, for COVID-19-induced acute respiratory distress syndrome (ARDS). COVID-
19 ARDS displays the typical features of diffuse alveolar damage with extensive pulmonary coagulation activation
resulting in fibrin deposition in the microvasculature and formation of hyaline membranes in the air sacs. Patients
infected with SARS-CoV-2 who manifest severe disease have high levels of inflammatory cytokines in plasma and
bronchoalveolar lavage fluid and significant coagulopathy. There is a strong association between the extent of the
coagulopathy and poor clinical outcomes.
The anti-coagulant actions of nebulised UFH limit fibrin deposition and microvascular thrombosis. Trials in patients
with acute lung injury and related conditions found inhaled UFH reduced pulmonary dead space, coagulation
activation, microvascular thrombosis and clinical deterioration, resulting in increased time free of ventilatory
support. In addition, UFH has anti-inflammatory, mucolytic and anti-viral properties and, specifically, has been
shown to inactivate the SARS-CoV-2 virus and prevent its entry into mammalian cells, thereby inhibiting pulmonary
infection by SARS-CoV-2. Furthermore, clinical studies have shown that inhaled UFH safely improves outcomes in
other inflammatory respiratory diseases and also acts as an effective mucolytic in sputum-producing respiratory
patients. UFH is widely available and inexpensive, which may make this treatment also accessible for low- and
middle-income countries.
These potentially important therapeutic properties of nebulised UFH underline the need for expedited large-scale
clinical trials to test its potential to reduce mortality in COVID-19 patients.
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Introduction
In December 2019, a novel coronavirus (severe acute re-
spiratory syndrome coronavirus 2, SARS-CoV-2)
emerged in China and has since spread globally. A large
proportion of patients admitted to hospital for
coronavirus disease 2019 (COVID-19) develop acute re-
spiratory distress syndrome (ARDS) criteria according to
the Berlin definition [1–3]. ARDS is an acute inflamma-
tory lung injury, associated with increased pulmonary
vascular permeability, increased lung weight and loss of
aerated lung tissue, affecting 23% of mechanically venti-
lated critically ill patients. The hospital mortality of
ARDS is estimated between 35 and 46% depending on
ARDS severity [4, 5]. However, the death rate in
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COVID-19 patients with ARDS appears to be higher, up
to 66% [2]. It has been suggested that COVID-19
pneumonia-associated ARDS is a specific disease or per-
haps a specific phenotype of ARDS, whose distinctive
features are severe hypoxaemia initially associated with
relatively well-preserved lung mechanics [6, 7]. A pos-
sible explanation for such severe hypoxaemia occurring
in compliant lungs is the loss of lung perfusion regula-
tion and hypoxic vasoconstriction. In addition, COVID-
19 ARDS patients have higher plasma markers of coagu-
lation, such as D-dimers, increased prothrombin time
and a lower platelet count [2, 8–12]. Endothelial dys-
function and microvascular thrombosis could therefore
also explain the specific pulmonary findings in severe
COVID-19—high dead space and impaired oxygenation
in the absence of significant decrease in pulmonary com-
pliance. Post-mortem studies and lung biopsies of
SARS-CoV-2 patients with ARDS indeed demonstrated
pulmonary fibrin deposition with hyaline membranes in
the alveolar spaces and extensive pulmonary micro-
vascular thrombi [13–15].
Pulmonary disease severity is also related to an aggres-
sive host inflammatory response to SARS-CoV-2 infec-
tion, with release of an uncontrolled cytokine storm
inflicting damage to other organs including the cardiac,
hepatic and renal systems [16].
In this focused review, we present the biological and sci-
entific rationale for the use of nebulised UFH for COVID-
19 pneumonia and ARDS in hospitalised patients and make
a call for an urgent, global approach to the investigation of
its therapeutic potential for this devastating condition.
Biological rationale: pathophysiology of COVID-19
The pathophysiology of COVID-19 associated ARDS is
summarised in Fig. 1a and is characterised by diffuse al-
veolar damage, hyperinflammation, coagulopathy, DNA
neutrophil extracellular traps (NETS), hyaline mem-
branes and microvascular thrombosis.
Infection, inflammation and coagulopathy
SARS-CoV-2 binds to angiotensin-converting enzyme-2
(ACE-2) to gain cellular entry. ACE-2 is widely expressed
Fig. 1 a Lung injury in coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin-
converting enzyme 2 (ACE-2) primarily on type II alveolar cells. After endocytosis of the viral complex, surface ACE-2 is downregulated, resulting
in unopposed angiotensin II accumulation. SARS-CoV-2 further causes lung injury through activation of residential macrophages, lymphocyte
apoptosis and neutrophils. The macrophages produce cytokines and chemokines, resulting in a cytokine storm. Inflammatory exudate rich in
plasma-borne coagulation factors enters the alveolar space, followed by expression of tissue factor by alveolar epithelial cells and macrophages
and the formation of fibrin and the hyaline membrane. Neutrophils in the alveoli cause formation of NETs, composed of extracellular DNA,
cytotoxic histones and neutrophil elastase, which cause further lung injury. COVID-19 also induces microvascular endothelial damage leading to
increased permeability, expression of tissue factor with coagulation activation and thrombus formation. b Proposed effects of inhaled nebulised
unfractionated heparin (UFH) in COVID-19 lung injury. UFH prevents SARS-CoV-2 from binding to ACE-2 and from entering the alveolar cells. UFH
reduces formation of the hyaline membrane and microvascular thrombosis, counteracts the hyperinflammation and the formation of NETs,
increases NO release with vasodilation and also has mucolytic properties. NETs, neutrophil extracellular traps; SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2; ACE-2, angiotensin-converting enzyme 2; COVID-19, coronavirus disease 2019. Permission was granted by © Beth Croce,
Bioperspective.com to reuse this figure
van Haren et al. Critical Care          (2020) 24:454 Page 2 of 11
in the lungs, predominantly on alveolar type II epithelial
cells, but also on bronchial epithelial cells and on arterial
and venous endothelial cells [17, 18]. ACE-2 hijacking pre-
vents angiotensin II degradation. Angiotensin II signals
through the type 1 angiotensin receptor, causing vasocon-
striction and lung injury, including endothelial injury lead-
ing to tissue factor expression and coagulation cascade
activation [19]. Widespread endothelial inflammation and
apoptosis leading to endothelial dysfunction in multiple
organs are associated with direct viral infection of endo-
thelial cells in COVID-19, as well as immune-mediated re-
sponses to infection of pulmonary alveolar cells, and a
pro-coagulant state [20].
Patients with SARS-CoV-2 who manifest severe dis-
ease, including ARDS, multi-organ failure, and death,
have higher plasma and BALF levels of inflammatory cy-
tokines (‘cytokine storm’); higher plasma markers of co-
agulation, such as D-dimers; and increased prothrombin
time and a lower platelet count [2, 8–11, 21–23]. An ag-
gressive dysfunctional inflammatory response following
pyroptosis of virus-infected cells is strongly implicated
in damage to the lungs [16]. For example, plasma con-
centrations of a range of pro-inflammatory cytokines
were higher in both ICU patients and non-ICU patients
infected with SARS-CoV-2 than in healthy adults, and
some of these agents were also higher in ICU patients
than non-ICU patients [9]. Furthermore, elevated plasma
IL-6 was reported to be a predictor of fatality, suggesting
that mortality might be driven by virally induced hyper-
inflammation [21, 22]. The expression of a large number
of cytokines is also elevated in BALF samples from
COVID-19 patients compared to control [23]. Finally,
intravascular DNA neutrophil extracellular traps (NETs)
have been reported in COVID-19 patients, where they
may contribute to cytokine release, coagulopathy and re-
spiratory failure [24, 25].
Hyaline membrane formation
COVID-19 is associated with the development of ARDS
displaying the typical features of diffuse alveolar damage
[26–30]. The hallmark histological feature of ARDS is a
fibrin mesh in the air sacs, known as a hyaline mem-
brane, on which leucocytes attach and manifest the in-
flammatory responses that result in diffuse alveolar
damage. Hyaline membrane formation is a consistent
and early manifestation of the inflammatory response in
ARDS [27, 30–33]. Hyaline membrane formation results
from entry into the alveolar space of inflammatory exud-
ate that is rich in plasma-borne coagulation factors. The
subsequent expression of tissue factor by alveolar epithe-
lial cells and macrophages triggers the conversion of
these coagulation factors to fibrin and the formation of
the hyaline membrane [34]. In pro-inflammatory condi-
tions, alveolar epithelial cells and macrophages also
express plasminogen activator inhibitor-1, which pre-
vents the removal of this membrane through endogen-
ous fibrinolysis [32, 35]. Pulmonary coagulation is
evident in increased markers of thrombin generation,
soluble tissue factor and factor VIIa activity found in
bronchoalveolar lavage fluid (BALF) from ARDS pa-
tients, together with an increased release of plasmino-
gen activator inhibitor-1 [36].
Hyaline membrane formation may contribute to lung
injury through a number of mechanisms. The hyaline
membrane forms a physical barrier thereby limiting the
diffusion of gases. Alveolar compliance and the action of
surfactant are also limited by fibrin formation in the al-
veoli contributing to atelectasis, and finally, the laying
down of a fibrin matrix may promote subsequent lung
fibrosis [32, 37].
Microvascular thrombosis
Fibrin accumulation in pulmonary capillaries and ve-
nules, which leads to microvascular thrombosis, is an
early feature of ARDS and the extent of this fibrin accu-
mulation correlates with the severity of lung injury [38–
41]. In response to inflammatory cytokines, the pulmon-
ary capillary beds, venules and arterioles express tissue
factor on endothelial cells and this triggers the conver-
sion of plasma coagulation factors to fibrin [42]. Cyto-
kine activation of NETosis and the presence of
intravascular NETs are further associated with the initi-
ation of thrombosis in arteries and veins, and NETs cir-
culating at high levels in COVID-19 can trigger micro-
embolic occlusion of small blood vessels in the lungs,
heart and kidneys [24, 25].
Extensive microvascular thrombosis has been demon-
strated in histological studies of ARDS [39, 40]. Angio-
graphic studies showed the extent of microvascular
obstruction correlated with the severity of respiratory
failure and with mortality [38, 39]. Microvascular throm-
bosis increases lung dead space and the increase in dead
space or its bedside surrogate ventilatory ratio was
shown to be an independent marker of mortality in
ARDS [43, 44]. Microvascular thrombosis also causes in-
creased pulmonary vascular resistance, which may result
in right heart failure [45].
There is a strong association between the extent of the
coagulopathy and poor clinical outcomes. In a case series of
183 COVID-19 patients, those who died had markedly ele-
vated D-dimers, elevated fibrin degradation products, lon-
ger prothrombin time and activated partial thromboplastin
time compared to survivors on admission, often meeting
criteria for disseminated intravascular coagulation [46].
Similar coagulation abnormalities were described in other
case series and elevated D-dimer levels were associated with
clinical outcomes [2, 47, 48]. In a Dutch case series of 184
COVID-19 positive patients, all of which received
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pharmacological thromboprophylaxis, the cumulative inci-
dence of a composite outcome comprised of symptomatic
pulmonary embolism (PE), deep-vein thrombosis, ischemic
stroke, myocardial infarction, or systemic arterial embolism
was 49%. The majority of thromboembolic events were PE
(87%) [49]. Another recent case series showed that
COVID-19 ARDS patients developed significantly more
thrombotic complications than non-COVID-19 ARDS pa-
tients, mainly PE [12].
Mucus exudates and DNA NETs
Excessive sputum production is a feature of approxi-
mately 30% of COVID-19 patients and the bronchi be-
come filled with desquamated epithelial cells, mucus and
thick mucus plugs [9, 50, 51]. Diapedesis of neutrophils
into the alveolar space is proposed to be a source of ex-
cess NETs, composed of extracellular DNA and bound
basic proteins including cytotoxic histones and neutro-
phil elastase, which are involved in both the generation
of NETs and damage to pulmonary tissue [25]. Such
NETs may further impair gas exchange and facilitate
secondary infections. Intra-alveolar NETS are a feature
of pneumonia-associated ARDS [52] and are likely to be
present in the airways of COVID-19 patients with
ARDS.
Biological rationale: effects of nebulised UFH
The effects of nebulised UFH in COVID-19 are sum-
marised in Fig. 1b. Nebulised UFH has anti-viral, anti-
coagulant, anti-inflammatory and mucolytic effects.
Anti-viral effects
Heparin is a member of a family of glycosaminoglycan
molecules that include heparan sulphate, chondroitin
sulphate, keratan sulphate and hyaluronic acid. These
molecules are expressed throughout the body, with di-
verse biological roles, and are usually associated with re-
spiratory and endothelial cell surfaces, basement
membrane and extracellular matrices [53]. In humans,
heparin is produced solely by mast cells and is stored in
granules, where it makes up 30% of the dry weight of
mast cell granules [54]. There is evidence that heparin
plays a role in host defence. Firstly, mast cells are mostly
located along blood vessels and are particularly associ-
ated with capillaries and post-capillary venules [55]. Sec-
ondly, organs exposed to the external environment, such
as the lungs and gut contain a large proportion of the
body’s mast cells [56]. Thirdly, heparin is conserved
across a variety of different species, some of which do
not have a blood coagulation system like ours (e.g. mol-
luscs), suggesting heparin has significant biological roles
unrelated to coagulation [57].
A large number of bacterial and viral pathogens de-
pend upon interactions with proteoglycan molecules
such as heparan sulphate, which is expressed on a range
of human tissue surfaces, for adhesion and invasion of
host tissues [53]. Several studies found heparin competes
with heparan sulphate for bacterial and viral adhesion
and may therefore limit pathogen invasion [58, 59]. For
example, heparin limits adhesion of Pseudomonas aeru-
ginosa, Burkholderia cenocepacia, Burkholderia pseudo-
mallei, Legionella pneumophila, Staphylococcus aureus,
Streptococcus pyogenes, Streptococcus pneumoniae, re-
spiratory syncytial virus and influenza A [60–64]. Hu-
man and animal studies suggest these actions may
reduce the development of pneumonia and bacteraemia
[58, 65].
Previous studies demonstrated that UFH prevented
SARS-associated coronavirus and other enveloped vi-
ruses such as human immunodeficiency virus and herpes
simplex virus, from attaching to and invading mamma-
lian cells [66–72]. A recent study demonstrated that the
SARS-CoV-2 Spike S1 protein receptor-binding domain
attaches to UFH and undergoes conformational change
that may prevent it from binding ACE-2 as a result [73].
Importantly, the binding of heparin to the receptor-
binding domain of the SARS-CoV-2 Spike S1 protein is
orders of magnitude stronger for full-chain length hep-
arin than low-+molecular weight heparins (LMWHs)
[74]. This anti-viral effect of heparin has recently been
confirmed in initial studies performed by Public Health
England where an UFH preparation produced a
concentration-dependent inhibition of SARS-CoV-2 in-
fection of Vero E6 cells that was more active than
LMWH, further suggesting that UFH may prevent inva-
sion of pulmonary epithelium and vascular endothelium
(M Carroll and J Tree, personal communication from
Public Health England). The high concentration of
SARS-Cov2 in the upper airways of COVID-19 patients
and the above anti-viral properties of heparin makes the
nebulised route of administration a unique and possibly
effective treatment for COVID-19.
Anti-inflammatory effects
Heparin also has other pharmacological actions of po-
tential benefit including inhibition of inflammatory cyto-
kines implicated in COVID-19 and the inhibition of
inflammatory cell recruitment into tissues via blocking
many of the key adhesion molecules expressed on vascu-
lar endothelium, improvement in lung function and in-
creased nitric oxide release [60, 75–78]. Heparin has
been shown to reduce the expression of pro-
inflammatory mediators in human alveolar macrophages
injured by lipopolysaccharide and to decrease the NF-kB
pathway in alveolar cells [79]. Furthermore, nebulised
heparin decreases pro-inflammatory cytokines in lung
tissue and the expression of NF-kB and TGF-β effectors
in alveolar macrophages [79, 80]. Heparin, through
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multiple actions including inhibition of adhesion mole-
cules and heparanase activity, has also been shown to re-
duce the infiltration of inflammatory cells into a range
of tissues, including the lung, activities that are inde-
pendent of its anti-coagulant properties [78]. Addition-
ally, heparin is known to have important inhibitory
effects on the complement cascade that has also been
implicated in the vascular injury associated with
COVID-19 [78]. In pre-clinical animal models, UFH was
a more effective anti-inflammatory agent than LMWHs,
which may be an important additional pharmacological
property of this drug in the context of the hyperinflam-
matory state associated with COVID-19 [78, 81].
Overall, the multiple pharmacological properties of
UFH may be important in the context of treating the
hyperinflammatory state associated with COVID-19,
particularly in the absence of clear evidence of the effi-
cacy of other anti-inflammatory therapies [82].
Anti-coagulant effects
Heparin’s anti-coagulant properties have been used in
clinical practice to limit systemic fibrin deposition since
1935 [83]. Heparin inhibits coagulation activation
through a range of mechanisms, including catalysing the
action of antithrombin, promoting tissue factor pathway
inhibitor expression, reducing tissue factor expression
and increasing endothelial expression of heparan
sulphate, and through release of tissue plasminogen acti-
vator by the endothelium.
Nebulised UFH targets pulmonary fibrin deposition
and inflammation, and local administration to the lungs
allows higher dosages and increases local efficacy, re-
duces the risk of systemic bleeding and is more effective
than intravenous administration [84, 85]. Importantly,
previous studies have shown that following nebulisation,
UFH does not enter the systemic circulation significantly
which means it can be used in addition to systemic
therapeutic or prophylactic anti-coagulation without
concerns of furthering systemic anti-coagulation. The
use of nebulised UFH in other respiratory settings was
not associated with local side effects in the lung includ-
ing bleeding [85–89].
Mucolytic effects
Mucus obstruction of the airways is compounded by the
presence of DNA NETs in inflammatory lung diseases
such as cystic fibrosis (CF), asthma, COPD and ARDS
[90]. DNA contributes to sputum elasticity and reduced
cough clearance, and in CF sputum, heparin disaggre-
gated DNA/actin bundles and activated endogenous
DNase to reduce sputum elasticity [91]. When DNA
NETS are broken down, the potential for the release of
cytotoxic histones, neutrophil elastase and IL-8
encrypted by the DNA is mitigated by the ability of
heparin to neutralise these basic proteins [90]. Inde-
pendently of the presence of DNA NETs, electrostatic
mucin interactions and viscosity are increased by a low
pH in airway surface liquid, as seen in cystic fibrosis
(CF), asthma, COPD and ARDS and these effects are
also reversed by heparin [92, 93]. The mucolytic proper-
ties of heparin have been utilised in the treatment of CF
patients with no safety issues and in particular inhaled
nebulised UFH has been used safely in patients who are
also receiving system anti-coagulation [94].
Pre-clinical and clinical evidence in lung injury
Animal studies of nebulised UFH in different acute lung
injury models have consistently shown a positive effect
on pulmonary coagulation, inflammation and oxygen-
ation (Table 1). Small human studies indicate that nebu-
lised heparin limits pulmonary fibrin deposition,
attenuates progression of acute lung injury and hastens
recovery (Table 2) [95, 96]. In smoke inhalation-related
lung injury, pre-clinical and clinical studies have sug-
gested that administration of inhaled anti-coagulants im-
proves oxygenation, reduces lung injury severity and
improves survival without altering systemic markers of
clotting and anti-coagulation [97].
Early-phase trials in patients with acute lung injury
and related conditions found that nebulised heparin re-
duced pulmonary dead space, coagulation activation,
microvascular thrombosis and deterioration in the Mur-
ray Lung Injury Score and increased time free of ventila-
tory support (Table 2) [98–102]. A multi-centre
randomised double-blind placebo-controlled trial of neb-
ulised heparin in 256 patients with or at risk of develop-
ing ARDS, investigated whether UFH accelerated
recovery and has been completed (B Dixon personal
communication, submitted for publication).
Clinical evidence in SARS-CoV-2
Published data suggest that patients with SARS-CoV-2
treated with systemic UFH or LMWH had better clinical
outcomes. For example, a non-randomised study found
patients with sepsis-induced coagulopathy and D-dimer
levels that were greater than 6-fold the upper limit of
normal, were more likely to survive if administered hep-
arin or LMWH [11]. In another observational study in
2773 patients hospitalised with COVID-19, mechanically
ventilated patients who received systemic anti-
coagulation during their hospital course had a lower
hospital mortality (adjusted HR of 0.86 per day, 95%
confidence interval 0.82–0.89, p < 0.001) [103]. This dif-
ference was not seen in all COVID-19 patients, suggest-
ing that the beneficial effects may be more pronounced
in patients with severe disease.
There are currently no published studies of nebulised
heparin in COVID-19 patients, but there are several in
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preparation or being conducted (Table 2). In the UK, a
study of nebulised UFH has been started under the na-
tional ACCORD programme (ACCORD 2: A Multicen-
tre, Seamless, Phase 2 Adaptive Randomisation Platform
Study to Assess the Efficacy and Safety of Multiple Can-
didate Agents for the Treatment of COVID 19 in Hospi-
talised Patients, EudraCT number 2020-001736-95).
This study is investigating the effects of nebulised UFH
administered 4 times daily in hospitalised patients test-
ing positive for SARS-CoV-2, but before patients require
ICU admission, on top of standard of care (Singh et al.,
personal communication). A multinational multi-centre
randomised open-label clinical trial to determine if treat-
ment with standard care and nebulised UFH, compared
to standard care alone, reduces the duration of invasive
mechanical ventilation in ICU patients with SARS-CoV-
2 study is currently in preparation (Dixon and van
Haren personal communication, ACTR
N12620000517976).
There is an urgent need for more large-scale clinical
trials to test whether nebulised UFH improves mortality
in COVID-19 patients. Ideally, these studies should be
Table 1 Pre-clinical studies of nebulised heparin treatment for acute lung injury
Dosage (Timing) Species Model (Sacrifice) Nebulizer Outcomes Side
effects
Reference
Animal models of acute lung injury treated with nebulised heparin
1000 IU/kg
(30min before injury and every 6h)
Rat it. Streptococcus
pneumoniae (40h)
Aeroneb
Pro
Nebulizer
↓ Pulmonary
coagulation
NR Hofstra et al,
2009 [104]
1000 IU/kg
(30min before, 6h and 12h after injury)
Rat iv. LPS (7.5 mg/kg)
(16h)
Aeroneb
Pro
Nebulizer
↓ Coagulation NR Hofstra et al,
2010 [105]
1000 IU/kg
(30min before injury and every 6h)
Rat it. Pseudomonas
aeruginosa (16h)
Aeroneb
Pro
Nebulizer
= NR Cornet et al,
2011 [106]
Dose NR
(5 min after injury)
Mouse inh. Chlorine (400
ppm for 30min) (6h)
AirLife
Brand
Misty Max
10
↓ Decreased
inflammation
No
side
effects
Zarogiannis
et al, 2014
[107]
1000 IU/kg
(4h and 8h after injury
or 30min before, 4h and 8h after injury)
Rat it. LPS (10μg/g)
(24h)
Aeroneb
Pro
Nebulizer
↓ Pulmonary
coagulation and
inflammation
NR Chimenti et
al, 2017 [80]
Animal models of acute lung injury treated with nebulised heparin and combined with another treatment
10000 IU (1h after injury, every 4h) Sheep Smoke inh. and it.
Pseudomonas
aeruginosa (24h)
AirLife
Brand
Misty Max
10
↓ Lung injury and
airways obstruction
↑ PaO2
No
side
effects
Murakami et
al, 2002 [108]
10000 IU (30min after injury, every 4h for 24h) or
combined with intravenous 10 mg/kg/h lisofylline
Sheep Smoke inh. (48h) AirLife
Brand
Misty Max
10
↓ Need for MV
↑ PaO2
No
side
effects
Tasaki et al,
2002 [109]
10000 IU (2h after injury, every 4h) or combined with
nebulized 290 IU recombinant antithrombin
Sheep Cutaneous burn
and smoke inh.
(48h)
AirLife
Brand
Misty Max
10
Combination:
↓ Pulmonary
inflammation and
airways obstruction
↑ PaO2
No
side
effects
Enkhbataar et
al, 2007 [110]
10000 IU (1h after injury, every 4h) combined with
intravenous 0.34 mg/kg/h recombinant antithrombin
Sheep Cutaneous burn
and smoke inh.
(48h)
AirLife
Brand
Misty Max
10
↓ Inflammation,
oedema, airways
obstruction
↑ PaO2
No
side
effects
Enkhbataar et
al, 2008 [111]
10000 IU (2h after injury, every 4h) combined with
intravenous 6 IU/kg/h recombinant antithrombin (from
1h after injury until the end of the study) and nebulized
2 mg tissue plasminogen inhibitor (4h after injury, every
4h)
Sheep Cutaneous burn
and smoke inh.
(48h)
AirLife
Brand
Misty Max
10
↓ Lung injury,
oedema and airways
obstruction
↑ PaO2
No
side
effects
Rehberg et al,
2014 [112]
1000 IU/kg (4h, 12h and 28h after injury) combined
with nebulized 500 IU/kg antithrombin (4h and 28h
after injury)
Rat it. HCl and LPS (30
μg/g) (72h)
Aeroneb
Pro
Nebulizer
↓ Pulmonary
coagulation and
inflammation
No
side
effects
Camprubí-
Rimblas et al,
2020 [113]
↓: reduced, ↑: increased, =: equal, inh inhalation, it. intratracheal, iv. intravenous, LPS lipopolysaccharide, MV mechanical ventilation, NR not reported
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Table 2 Clinical studies of nebulised heparin treatment for acute lung injury
Dosage (Timing) Patients n Nebulizer Outcomes Reference
Clinical studies of acute respiratory distress syndrome with nebulised heparin
50000-400000 IU/day (two
days)
MV ARDS
Open-label phase 1 trial
16 Aeroneb
Pro
Nebulizer
↓systemic
coagulation
(↓ pulmonary
coagulation,
400000 IU)
Dixon et al,
2008 [114]
25000 IU (every 4h or 6h, max
14 days)
> 48h MV
RCT
50 Aeroneb
Pro
Nebulizer
↓systemic
coagulation
↑ Free days MV
Dixon et al,
2010 [100]
5000 IU (four times a day
until cease MV or discharge
from the UCI)
> 48h MV
Phase 2 RCT
214 Aeroneb
Pro
Nebulizer
= Bandeshe
et al, 2016
[115]
50000 IU (one day) Elective cardiac surgery
RCT
40 Aeroneb
Pro
Nebulizer
↓ alveolar dead
space fraction and
tidal volumes
Dixon et al,
2016 [101]
25000 IU (every 6h, 10 days) MV ARDS
RCT
256 Aeroneb
Pro
Nebulizer
↓Lung injury
↑ 60 day survivors
at home
Dixon et al,
2020
(submitted
for
publication)
Clinical studies of acute respiratory distress syndrome with nebulised heparin and combined with another treatment
5000 IU combined with N-
acetylcysteine and
bronchodilator (every 4h for 7
days)
Burn patients paediatric
Retrospective
90 (children) NR ↓atelectasis,
reintubation and
mortality
Desai et al,
1999 [116]
5000 IU combined N-
acetylcystine and
bronchodilator (every 4h for 7
days)
Burn patients
Retrospective
150 (children/
adults)
NR = Holt et al,
2008 [117]
10000 IU combined N-
acetylcystine and
bronchodilator (every 4h for 7
days)
Burn patients
Retrospective
30 NR ↓ lung injury
↓ mortality
↑ oxygenation
Miller et al,
2009 [118]
5000 IU combined N-
acetylcystine and
bronchodilator (every 4h for 7
days)
Burn patients
Retrospective
63 NR = Yip et al,
2011 [119]
5000 IU combined N-
acetylcystine and
bronchodilator (every 4h for 7
days)
Burn patients
Retrospective
40 NR = Kashefi et
al, 2014
[120]
10000 IU combined N-
acetylcystine and
bronchodilator (every 4h for 7
days)
Burn patients
Retrospective
72 NR ↑ free days MV McIntire et
al, 2017
[121]
25000 IU (every 4h for 14
days)
Burn patients
RCT (terminated, insufficient recruitment of
patients and high costs associated with the
purchase and blinding of study medication)
160 Aeroneb
Pro
Nebulizer
Not available Glas et al,
2014 [122]
Clinical studies of COVID-19 with nebulised heparin
25000 IU (every 6h for 10
days)
SARS CoV 2 infection, on MV RCT
ACTRN:
12620000517976
Aeroneb
Pro
Nebulizer
On-going Dixon et al,
2020 [123]
25000 IU (every 6h up to 21
days)
SARS CoV 2 infection, pre-ICU RCT
EudraCT: 2020-
001736-95
Aeroneb
Pro
Nebulizer
On-going ACCORD-2
(NHS UK)
↓: reduced, ↑: increased, =: equal, MV mechanical ventilation, RCT randomized controlled trial, NR not reported
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linked together by a global network with the objective of
standardising key outcomes, so a prospective individual
patient meta-analysis (so called ‘meta-trial’) can be per-
formed, to provide a rapid more generalisable answer to
the question.
Conclusion
Severe COVID-19 is characterised by diffuse alveolar
damage, hyperinflammation, coagulopathy, DNA neutro-
phil extracellular traps (NETS) and microvascular
thrombosis. There is a strong scientific and biological
basis to test the use of nebulised UFH as a therapy for
COVID-19 pneumonia and ARDS. UFH prevents SARS-
CoV-2 from binding to ACE-2 and infecting cells and
has relevant anti-coagulant, anti-inflammatory and mu-
colytic effects. Because of these multiple modes of ac-
tion, inhaled UFH may offer clinical benefit across the
time course of the disease. As an anti-viral, delivered via
inhalation to the upper airways, the major point of entry
of the virus, UHF may prevent infection and be a
prophylactic treatment. If administered via nebulisation
at the development of symptoms, its multiple properties
may attenuate disease progression. As the disease pro-
gresses, UFH’s anti-inflammatory and anti-coagulant
properties may be used to treat COVID-19-associated
ARDS. In the pneumonic phase of COVID-19, which is
typified by excess production of mucus, nebulised UFH’s
known mucolytic effect can be used to aid recovery.
UFH is an inexpensive drug and widely available and
its use as a potentially effective treatment for COVID-19
may have important humanitarian and economic impli-
cations especially for low- and middle-income countries.
The potential therapeutic properties underline the
need for expedited large-scale clinical trials of nebulised
UFH to test its potential to reduce mortality in COVID-
19 patients.
Acknowledgements
The authors wish to acknowledge Ms. Beth Croce, medical illustrator, for
designing the figure for this manuscript.
Authors’ contributions
FvH drafted the manuscript. All authors contributed equally to revision and
finalisation of the manuscript. The authors read and approved the final
manuscript.
Funding
No funding was obtained for this work.
Availability of data and materials
The datasets used for the current manuscript are available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
FvH, CP, JL, QN, RS, BD, JT and MC have nothing to disclose. TW is Chief
Investigator of the ACCORD COVID Research Programme. AA and MCR
report grants from Grifols, outside the submitted work. JS is the Scientific
Director of Ockham Biotech Ltd., a company that owns patents around the
use of inhaled heparin. DS reports personal fees from AstraZeneca, personal
fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees
from Cipla, personal fees from Genentech, personal fees from
GlaxoSmithKline, personal fees from Glenmark, personal fees from
Gossamerbio, personal fees from Menarini, personal fees from Mundipharma,
personal fees from Novartis, personal fees from Peptinnovate, personal fees
from Pfizer, personal fees from Pulmatrix, personal fees from Theravance and
personal fees from Verona, outside the submitted work.
Author details
1Australian National University, Medical School, Canberra, Australia. 2Intensive
Care Unit, the Canberra Hospital, Canberra, Australia. 3Sackler Institute of
Pulmonary Pharmacology, King’s College London, London, UK. 4Anaesthesia
and Intensive Care Medicine, School of Medicine, and Regenerative Medicine
Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices,
Biomedical Sciences Building, National University of Ireland Galway, Galway,
Ireland. 5Department of Anaesthesia, University Hospital Galway, Saolta
Hospital Group, Galway, Ireland. 6Critical Center, Corporació Sanitaria Parc
Tauli , CIBER Enfermedades Respiratorias, Autonomous University of
Barcelona, Sabadell, Spain. 7Institut d’Investigació I Innovació Parc Tauli (I3PT),
CIBER de Enfermedades Respiratorias, Sabadell, Spain. 8Institute of Systems,
Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
9Department of Critical Care Medicine, St Vincent’s Hospital, Melbourne,
Australia. 10School of Pharmacy and Biomedical Science, University of
Portsmouth, Portsmouth, UK. 11Department of Respiratory Medicine,
University of Southampton, Southampton, UK. 12National Infection Service,
Public Health England, Porton Down, UK. 13Medicines Evaluation Unit,
University of Manchester, Manchester, UK.
Received: 16 June 2020 Accepted: 3 July 2020
References
1. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda
D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S,
Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti
A, Network C-LI, Nailescu A, Corona A, Zangrillo A, Protti A, Albertin A,
Forastieri Molinari A, Lombardo A, Pezzi A, Benini A, Scandroglio AM, Malara
A, Castelli A, Coluccello A, Micucci A, Pesenti A, Sala A, Alborghetti A,
Antonini B, Capra C, Troiano C, Roscitano C, Radrizzani D, Chiumello D,
Coppini D, Guzzon D, Costantini E, Malpetti E, Zoia E, Catena E, Agosteo E,
Barbara E, Beretta E, Boselli E, Storti E, Harizay F, Della Mura F, Lorini FL,
Donato Sigurta F, Marino F, Mojoli F, Rasulo F, Grasselli G, Casella G, De
Filippi G, Castelli G, Aldegheri G, Gallioli G, Lotti G, Albano G, Landoni G,
Marino G, Vitale G, Battista Perego G, Evasi G, Citerio G, Foti G, Natalini G,
Merli G, Sforzini I, Bianciardi L, Carnevale L, Grazioli L, Cabrini L, Guatteri L,
Salvi L, Dei Poli M, Galletti M, Gemma M, Ranucci M, Riccio M, Borelli M,
Zambon M, Subert M, Cecconi M, Mazzoni MG, Raimondi M, Panigada M,
Belliato M, Bronzini N, Latronico N, Petrucci N, Belgiorno N, Tagliabue P,
Cortellazzi P, Gnesin P, Grosso P, Gritti P, Perazzo P, Severgnini P, Ruggeri P,
Sebastiano P, Covello RD, Fernandez-Olmos R, Fumagalli R, Keim R, Rona R,
Valsecchi R, Cattaneo S, Colombo S, Cirri S, Bonazzi S, Greco S, Muttini S,
Langer T, Alaimo V, Viola U. Baseline characteristics and outcomes of 1591
patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy
Region, Italy. JAMA. 2020;323(16):1574–81. https://doi.org/10.1001/jama.2020.
5394.
2. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C,
Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W,
Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk factors associated with
acute respiratory distress syndrome and death in patients with coronavirus
disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):
934–43. https://doi.org/10.1001/jamainternmed.2020.0994.
3. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E,
Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin
definition. JAMA. 2012;307(23):2526–33.
van Haren et al. Critical Care          (2020) 24:454 Page 8 of 11
4. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van
Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT,
Wrigge H, Slutsky AS, Pesenti A, Investigators LS, Group ET. Epidemiology,
patterns of care, and mortality for patients with acute respiratory distress
syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–
800.
5. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N
Engl J Med. 2017;377(6):562–72.
6. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L,
Camporota L. COVID-19 pneumonia: different respiratory treatments for
different phenotypes? Intensive Care Med. 2020;46:1099–102. https://doi.
org/10.1007/s00134-020-06033-2.
7. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA.
2020;323(22):2329–30. https://doi.org/10.1001/jama.2020.6825.
8. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W,
Tian D-S. Dysregulation of immune response in patients with COVID-19 in
Wuhan, China. Clinical Infectious Diseases. 2020;ciaa248. https://doi.org/10.
1093/cid/ciaa248.
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H,
Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan. China Lancet.
2020;395(10223):497–506.
10. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, Wang K, Leng F, Wei S,
Chen L, Liu HG. Clinical characteristics of fatal and recovered cases of
coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study.
Chin Med J. 2020;133(11):1261–7. https://doi.org/10.1097/CM9.
0000000000000824.
11. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is
associated with decreased mortality in severe coronavirus disease 2019
patients with coagulopathy. J Thromb Haemost. 2020;18:1094–9. https://doi.
org/10.1111/jth.14817.
12. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X,
Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain
V, Schneider F, Grunebaum L, Angles-Cano E, Sattler L, Mertes PM, Meziani
F, Group CT. High risk of thrombosis in patients with severe SARS-CoV-2
infection: a multicenter prospective cohort study. Intensive Care Med. 2020;
46:1089–98. https://doi.org/10.1007/s00134-020-06062-x.
13. Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, Zhang S, Cao T, Yang C, Li
M, Guo G, Chen X, Chen Y, Lei M, Liu H, Zhao J, Peng P, Wang CY, Du R.
Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a
patient with COVID-19. Ann Intern Med. 2020;172(9):629–32. https://doi.org/
10.7326/M20-0533.
14. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F,
Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk
D. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in
Covid-19. N Engl J Med. 2020;383:120–8. https://doi.org/10.1056/
NEJMoa2015432.
15. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, Mou HM, Wang LH, Zhang
HR, Fu WJ, Luo T, Liu F, Guo QN, Chen C, Xiao HL, Guo HT, Lin S, Xiang DF,
Shi Y, Pan GQ, Li QR, Huang X, Cui Y, Liu XZ, Tang W, Pan PF, Huang XQ,
Ding YQ, Bian XW. A pathological report of three COVID-19 cases by
minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49(5):411–7.
16. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19:
immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–
74.https://doi.org/10.1038/s41577-020-0311-8.
17. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue
distribution of ACE2 protein, the functional receptor for SARS coronavirus. A
first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.
18. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression
profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv
2020(2020.01.26.919985).
19. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting
enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and
potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
20. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS,
Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection
and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.
21. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Hlh
Across Speciality Collaboration UK. COVID-19: consider cytokine storm
syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.
22. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality
due to COVID-19 based on an analysis of data of 150 patients from Wuhan,
China. Intensive Care Med. 2020;46(5):846–8.
23. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu
H, Lin Y, Zhang M, Zhang Q, Shi M, Liu Y, Zhou Y, Lan K, Chen Y. Transcriptomic
characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear
cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–70.
24. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair CN, Weber
A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS. Neutrophil
extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. https://doi.
org/10.1172/jci.insight.138999.
25. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J,
Crawford JM, Dassler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M,
Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S,
Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting
potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med
2020:217(6):e20200652. https://doi.org/10.1084/jem.20200652.
26. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K,
Bargfrieder U, Trauner M. Pulmonary arterial thrombosis in COVID-19 with
fatal outcome: results from a prospective, single-center, clinicopathologic
case series. Ann Intern Med. 2020. https://doi.org/10.7326/M20-2566.
27. Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann
A, Heinrich F, Mushumba H, Kniep I, Schroder AS, Burdelski C, de Heer G,
Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth
A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C,
Addo MM, Aepfelbacher M, Puschel K, Kluge S. Autopsy findings and
venous thromboembolism in patients with COVID-19: a prospective cohort
study. Ann Intern Med. 2020. https://doi.org/10.7326/M20-2003.
28. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF,
Pierre de Oliveira E, Nascimento Saldiva PH, Mauad T, Marcia Negri E.
Pathological evidence of pulmonary thrombotic phenomena in severe
COVID-19. J Thromb Haemost. 2020;18(6):1517–9. https://doi.org/10.1111/jth.
14844.
29. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L,
Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological
findings of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 2020;8(4):420–2.
30. Adachi T, Chong JM, Nakajima N, Sano M, Yamazaki J, Miyamoto I, Nishioka
H, Akita H, Sato Y, Kataoka M, Katano H, Tobiume M, Sekizuka T, Itokawa K,
Kuroda M, Suzuki T. Clinicopathologic and immunohistochemical findings
from autopsy of patient with COVID-19, Japan. Emerg Infect Dis 2020: 26(9).
31. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J
Med. 2000;342(18):1334–49.
32. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
Crit Care Med. 2003;31(4 Suppl):S213–20.
33. Burns AR, Smith CW, Walker DC. Unique structural features that influence
neutrophil emigration into the lung. Physiol Rev. 2003;83(2):309–36.
34. Bastarache JA, Wang L, Geiser T, Wang Z, Albertine KH, Matthay MA, Ware
LB. The alveolar epithelium can initiate the extrinsic coagulation cascade
through expression of tissue factor. Thorax. 2007;62(7):608–16.
35. Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human
acute lung injury--new therapeutic targets? Keio J Med. 2005;54(3):142–9.
36. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P,
Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar
fibrin formation caused by enhanced procoagulant and depressed
fibrinolytic capacities in severe pneumonia. Comparison with the acute
respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161(2 Pt 1):
454–62.
37. Gunther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D,
Seeger W. Surfactant alteration and replacement in acute respiratory distress
syndrome. Respir Res. 2001;2(6):353–64.
38. Greene R, Zapol WM, Snider MT, Reid L, Snow R, O'Connell RS, Novelline RA.
Early bedside detection of pulmonary vascular occlusion during acute
respiratory failure. Am Rev Respir Dis. 1981;124(5):593–601.
39. Tomashefski JF Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The
pulmonary vascular lesions of the adult respiratory distress syndrome. Am J
Pathol. 1983;112(1):112–26.
40. Blaisdell FW. Pathophysiology of the respiratory distress syndrome. Arch
Surg. 1974;108(1):44–9.
41. Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive
Care. 2004;32(5):619–29.
van Haren et al. Critical Care          (2020) 24:454 Page 9 of 11
42. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S,
Zahler S, Preissner K, Engelmann B. Intravascular tissue factor initiates
coagulation via circulating microvesicles and platelets. FASEB J. 2003;17(3):
476–8. https://doi.org/10.1096/fj.02-0574fje.
43. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay
MA. Pulmonary dead-space fraction as a risk factor for death in the acute
respiratory distress syndrome. N Engl J Med. 2002;346(17):1281–6.
44. Sinha P, Calfee CS, Beitler JR, Soni N, Ho K, Matthay MA, Kallet RH.
Physiologic analysis and clinical performance of the Ventilatory ratio in
acute respiratory distress syndrome. Am J Respir Crit Care Med. 2019;199(3):
333–41.
45. Cooper JR, Jr., Abrams J, Frazier OH, Radovancevic R, Radovancevic B, Bracey
AW, Kindo MJ, Gregoric ID. Fatal pulmonary microthrombi during surgical
therapy for end-stage heart failure: possible association with antifibrinolytic
therapy. J Thorac Cardiovasc Surg 2006: 131(5): 963–968.
46. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are
associated with poor prognosis in patients with novel coronavirus
pneumonia. J Thromb Haemost. 2020;18(4):844–7.
47. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection.
Clin Chem Lab Med. 2020;58(7). https://doi.org/10.1515/cclm-2020-0198.
48. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan
L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and
risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:
a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
49. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM,
Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H.
Confirmation of the high cumulative incidence of thrombotic complications
in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res.
2020;191:148–50.
50. Medicine NHCSAoTC. Diagnosis and treatment protocol for novel
coronavirus pneumonia. National Health Commission & State Administration
of Traditional Chinese Medicine on March 3, 2020 2020.
51. Mao Y, Lin W, Wen J, Chen G. Clinical and pathological characteristics of
2019 novel coronavirus disease (COVID-19): a systematic review. medRxiv
2020(2020.02.20.20025601).
52. Bendib I, de Chaisemartin L, Granger V, Schlemmer F, Maitre B, Hue S,
Surenaud M, Beldi-Ferchiou A, Carteaux G, Razazi K, Chollet-Martin S,
Mekontso Dessap A, de Prost N. Neutrophil extracellular traps are elevated
in patients with pneumonia-related acute respiratory distress syndrome.
Anesthesiology. 2019;130(4):581–91.
53. Rostand KS, Esko JD. Microbial adherence to and invasion through
proteoglycans. Infect Immun. 1997;65(1):1–8.
54. Carr J. The anti-inflammatory action of heparin: heparin as an antagonist to
histamine, bradykinin and prostaglandin E1. Thromb Res. 1979;16(3–4):507–16.
55. Porzionato A, Macchi V, Parenti A, De Caro R. The distribution of mast cells
in the human area postrema. J Anat. 2004;204(2):141–7.
56. Valent P, Baghestanian M, Bankl HC, Sillaber C, Sperr WR, Wojta J, Binder BR,
Lechner K. New aspects in thrombosis research: possible role of mast cells
as profibrinolytic and antithrombotic cells. Thromb Haemost. 2002;87(5):
786–90.
57. Nader HB, Chavante SF, dos-Santos EA, Oliveira TW, de-Paiva JF, Jeronimo
SM, Medeiros GF, de-Abreu LR, Leite EL, de-Sousa-Filho JF, Castro RA, Toma
L, Tersariol IL, Porcionatto MA, Dietrich CP. Heparan sulfates and heparins:
similar compounds performing the same functions in vertebrates and
invertebrates? Braz J Med Biol Res 1999: 32(5): 529–538.
58. Idanpaan-Heikkila I, Simon PM, Zopf D, Vullo T, Cahill P, Sokol K,
Tuomanen E. Oligosaccharides interfere with the establishment and
progression of experimental pneumococcal pneumonia. J Infect Dis.
1997;176(3):704–12.
59. Bryan R, Feldman M, Jawetz SC, Rajan S, DiMango E, Tang HB, Scheffler L,
Speert DP, Prince A. The effects of aerosolized dextran in a mouse model of
Pseudomonas aeruginosa pulmonary infection. J Infect Dis. 1999;179(6):
1449–58.
60. Thomas R, Brooks T. Common oligosaccharide moieties inhibit the
adherence of typical and atypical respiratory pathogens. J Med Microbiol.
2004;53(Pt 9):833–40.
61. Liang OD, Ascencio F, Fransson LA, Wadstrom T. Binding of heparan sulfate
to Staphylococcus aureus. Infect Immun. 1992;60(3):899–906.
62. Tsang KW, Shum DK, Chan S, Ng P, Mak J, Leung R, Shum IH, Ooi GC, Tipoe
GL, Lam WK. Pseudomonas aeruginosa adherence to human basement
membrane collagen in vitro. Eur Respir J. 2003;21(6):932–8.
63. Martinez I, Melero JA. Binding of human respiratory syncytial virus to cells:
implication of sulfated cell surface proteoglycans. J Gen Virol. 2000;81(Pt 11):
2715–22.
64. Hosoya M, Balzarini J, Shigeta S, De Clercq E. Differential inhibitory effects of
sulfated polysaccharides and polymers on the replication of various
myxoviruses and retroviruses, depending on the composition of the target
amino acid sequences of the viral envelope glycoproteins. Antimicrob
Agents Chemother. 1991;35(12):2515–20.
65. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce
thrombotic and infective complications in critically ill children. Intensive
Care Med. 2000;26(7):967–72.
66. Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G, Jiang C. Inhibition of SARS
pseudovirus cell entry by lactoferrin binding to heparan sulfate
proteoglycans. PLoS One. 2011;6(8):e23710.
67. Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, Lazzarin A, Bordignon
C, Poli G, Clementi M. Coronaviridae and SARS-associated coronavirus strain
HSR1. Emerg Infect Dis. 2004;10(3):413–8.
68. de Haan CA, Li Z, te Lintelo E, Bosch BJ, Haijema BJ, Rottier PJ. Murine
coronavirus with an extended host range uses heparan sulfate as an entry
receptor. J Virol. 2005;79(22):14451–6.
69. Madu IG, Chu VC, Lee H, Regan AD, Bauman BE, Whittaker GR. Heparan
sulfate is a selective attachment factor for the avian coronavirus infectious
bronchitis virus Beaudette. Avian Dis. 2007;51(1):45–51.
70. Cagno V, Tseligka ED, Jones ST, Tapparel C. Heparan Sulfate Proteoglycans and
Viral Attachment: True Receptors or Adaptation Bias? Viruses 2019: 11(7).
71. Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K. Human
coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to
target cells. J Virol. 2014;88(22):13221–30.
72. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L,
Olson W, Kwong PD, Sattentau QJ. Selective interactions of polyanions with
basic surfaces on human immunodeficiency virus type 1 gp120. J Virol.
2000;74(4):1948–60.
73. Mycroft-West C, Su D, Elli S, Guimond S, Miller G, Turnbull J, Yates E, Guerrini
M, Fernig D, Lima M, Skidmore M. The 2019 coronavirus (SARS-CoV-2)
surface protein (Spike) S1 Receptor Binding Domain undergoes
conformational change upon heparin binding. bioRxiv 2020. https://doi.org/
10.1101/2020.02.29.971093.
74. Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM, Fu L,
Dordick JS, Woods RJ, Zhang F, Linhardt RJ. Glycosaminoglycan binding
motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate
novel coronavirus (SARS-CoV-2) host cell entry. bioRxiv 2020. https://doi.org/
10.1101/2020.04.14.041459.
75. Tangphao O, Chalon S, Moreno HJ Jr, Abiose AK, Blaschke TF, Hoffman BB.
Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther.
1999;66(3):232–8.
76. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-
induced asthma with inhaled heparin. N Engl J Med. 1993;329(2):90–5.
77. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions
of heparin and heparan sulfate glycosaminoglycans with the selectins.
Implications for the use of unfractionated and low molecular weight
heparins as therapeutic agents. J Clin Invest. 1998;101(4):877–89.
78. Mulloy B. The non-anticoagulant promise of heparin and its mimetics. Curr
Opin Pharmacol. 2019;46:50–4.
79. Camprubi-Rimblas M, Guillamat-Prats R, Lebouvier T, Bringue J, Chimenti L,
Iglesias M, Obiols C, Tijero J, Blanch L, Artigas A. Role of heparin in
pulmonary cell populations in an in-vitro model of acute lung injury. Respir
Res. 2017;18(1):89.
80. Chimenti L, Camprubi-Rimblas M, Guillamat-Prats R, Gomez MN, Tijero J,
Blanch L, Artigas A. Nebulized heparin attenuates pulmonary coagulopathy
and inflammation through alveolar macrophages in a rat model of acute
lung injury. Thromb Haemost. 2017;117(11):2125–34.
81. Lever R, Smailbegovic A, Page CP. Locally available heparin modulates
inflammatory cell recruitment in a manner independent of anticoagulant
activity. Eur J Pharmacol. 2010;630(1–3):137–44.
82. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X,
Yan X, Zeng X, Zhang S. The use of anti-inflammatory drugs in the
treatment of people with severe coronavirus disease 2019 (COVID-19): the
perspectives of clinical immunologists from China. Clin Immunol. 2020;214:
108393.
83. Fellner SK, Purkerson ML. Gordon Murray: heparin, hemodialysis and hubris.
Am J Nephrol. 2002;22(2–3):271–7.
van Haren et al. Critical Care          (2020) 24:454 Page 10 of 11
84. Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ. Nebulized
anticoagulants for acute lung injury - a systematic review of preclinical and
clinical investigations. Crit Care. 2012;16(2):R70.
85. Camprubi-Rimblas M, Tantinya N, Bringue J, Guillamat-Prats R, Artigas A.
Anticoagulant therapy in acute respiratory distress syndrome. Ann Transl
Med. 2018;6(2):36.
86. Monagle K, Ryan A, Hepponstall M, Mertyn E, Monagle P, Ignjatovic V,
Newall F. Inhalational use of antithrombotics in humans: review of the
literature. Thromb Res. 2015;136(6):1059–66.
87. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory
effects of heparin and its derivatives: a systematic review. Adv Pharmacol
Sci. 2015;2015:507151.
88. Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of heparin
and related drugs. Pharmacol Rev. 2016;68(1):76–141.
89. Shute JK, Calzetta L, Cardaci V, di Toro S, Page CP, Cazzola M. Inhaled
nebulised unfractionated heparin improves lung function in moderate to
very severe COPD: a pilot study. Pulm Pharmacol Ther. 2018;48:88–96.
90. Porto BN, Stein RT. Neutrophil extracellular traps in pulmonary diseases: too
much of a good thing? Front Immunol. 2016;7:311.
91. Broughton-Head VJ, Shur J, Carroll MP, Smith JR, Shute JK. Unfractionated
heparin reduces the elasticity of sputum from patients with cystic fibrosis.
Am J Physiol Lung Cellular Molecular Physiol. 2007;293(5):L1240–9.
92. Ricciardolo FL, Gaston B, Hunt J. Acid stress in the pathology of asthma. J
Allergy Clin Immunol. 2004;113(4):610–9.
93. Tang XX, Ostedgaard LS, Hoegger MJ, Moninger TO, Karp PH, McMenimen
JD, Choudhury B, Varki A, Stoltz DA, Welsh MJ. Acidic pH increases airway
surface liquid viscosity in cystic fibrosis. J Clin Invest 2016: 126(3): 879–891.
94. Serisier DJ, Shute JK, Hockey PM, Higgins B, Conway J, Carroll MP. Inhaled
heparin in cystic fibrosis. Eur Respiratory J. 2006;27(2):354–8.
95. Juschten J, Tuinman PR, Juffermans NP, Dixon B, Levi M, Schultz MJ.
Nebulized anticoagulants in lung injury in critically ill patients-an updated
systematic review of preclinical and clinical studies. Ann Transl Med. 2017;
5(22):444.
96. Glas GJ, Serpa Neto A, Horn J, Cochran A, Dixon B, Elamin EM, Faraklas I,
Dissanaike S, Miller AC, Schultz MJ. Nebulized heparin for patients under
mechanical ventilation: an individual patient data meta-analysis. Ann
Intensive Care. 2016;6(1):33.
97. Miller AC, Elamin EM, Suffredini AF. Inhaled anticoagulation regimens for
the treatment of smoke inhalation-associated acute lung injury: a systematic
review. Crit Care Med. 2014;42(2):413–9.
98. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized
heparin reduces levels of pulmonary coagulation activation in acute lung
injury. Crit Care. 2010;14(5):445.
99. Dixon B, Campbell DJ, Santamaria JD. Elevated pulmonary dead space and
coagulation abnormalities suggest lung microvascular thrombosis in patients
undergoing cardiac surgery. Intensive Care Med. 2008;34(7):1216–23.
100. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized
heparin is associated with fewer days of mechanical ventilation in critically ill
patients: a randomized controlled trial. Crit Care. 2010;14(5):R180.
101. Dixon B, Smith R, Santamaria JD, Orford NR, Wakefield BJ, Ives K, McKenzie
R, Zhang B, Yap CH. A trial of nebulised heparin to limit lung injury
following cardiac surgery. Anaesth Intensive Care. 2016;44(1):28–33.
102. Dixon B, Smith R. Nebulised Heparin for Lung Injury - Clinical Protocol V1:
St.Vincent’s Hospital Melbourne Australia; 2011.
103. Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, Charney AW,
Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of
treatment dose anticoagulation with in-hospital survival among hospitalized
patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–4.
104. Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, Zaat SA,
Schultz MJ. Nebulized antithrombin limits bacterial outgrowth and lung injury
in Streptococcus pneumoniae pneumonia in rats. Crit Care. 2009;13(5):R145.
105. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G, van der Poll T,
Levi M, Schultz MJ. Nebulized anticoagulants limit pulmonary coagulopathy,
but not inflammation, in a model of experimental lung injury. J Aerosol
Med Pulm Drug Deliv. 2010;23(2):105–11.
106. Cornet AD, Hofstra JJ, Vlaar AP, van den Boogaard FE, Roelofs JJ, van der
Poll T, Levi M, Groeneveld AB, Schultz MJ. Nebulized anticoagulants limit
coagulopathy but not inflammation in Pseudomonas aeruginosa-induced
pneumonia in rats. Shock. 2011;36(4):417–23.
107. Zarogiannis SG, Wagener BM, Basappa S, Doran S, Rodriguez CA,
Jurkuvenaite A, Pittet JF, Matalon S. Postexposure aerosolized heparin
reduces lung injury in chlorine-exposed mice. Am J Physiol Lung Cell Mol
Physiol. 2014;307(5):L347–54.
108. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber
LD, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL. Heparin
nebulization attenuates acute lung injury in sepsis following smoke
inhalation in sheep. Shock. 2002;18(3):236–41.
109. Tasaki O, Mozingo DW, Dubick MA, Goodwin CW, Yantis LD, Pruitt BA Jr.
Effects of heparin and lisofylline on pulmonary function after smoke
inhalation injury in an ovine model. Crit Care Med. 2002;30(3):637–43.
110. Enkhbaatar P, Cox RA, Traber LD, Westphal M, Aimalohi E, Morita N, Prough
DS, Herndon DN, Traber DL. Aerosolized anticoagulants ameliorate acute
lung injury in sheep after exposure to burn and smoke inhalation. Crit Care
Med. 2007;35(12):2805–10.
111. Enkhbaatar P, Esechie A, Wang J, Cox RA, Nakano Y, Hamahata A, Lange M,
Traber LD, Prough DS, Herndon DN, Traber DL. Combined anticoagulants
ameliorate acute lung injury in sheep after burn and smoke inhalation. Clin
Sci (Lond). 2008;114(4):321–9.
112. Rehberg S, Yamamoto Y, Sousse LE, Jonkam C, Cox RA, Prough DS, Enkhbaatar
P. Advantages and pitfalls of combining intravenous antithrombin with
nebulized heparin and tissue plasminogen activator in acute respiratory
distress syndrome. J Trauma Acute Care Surg. 2014;76(1):126–33.
113. Camprubi-Rimblas M, Tantinya N, Guillamat-Prats R, Bringue J, Puig F,
Gomez MN, Blanch L, Artigas A. Effects of nebulized antithrombin and
heparin on inflammatory and coagulation alterations in an acute lung injury
model in rats. J Thromb Haemost. 2020;18(3):571–83.
114. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin
in acute lung injury. Crit Care. 2008;12(3):R64.
115. Bandeshe H, Boots R, Dulhunty J, Dunlop R, Holley A, Jarrett P, Gomersall
CD, Lipman J, Lo T, O'Donoghue S, Paratz J, Paterson D, Roberts JA, Starr T,
Stephens D, Stuart J, Thomas J, Udy A, White H. Is inhaled prophylactic
heparin useful for prevention and management of pneumonia in ventilated
ICU patients?: the IPHIVAP investigators of the Australian and New Zealand
Intensive Care Society Clinical Trials Group. J Crit Care. 2016;34:95–102.
116. Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. Reduction in
mortality in pediatric patients with inhalation injury with aerosolized
heparin/N-acetylcystine [correction of acetylcystine] therapy. J Burn Care
Rehabil. 1998;19(3):210–2.
117. Holt J, Saffle JR, Morris SE, Cochran A. Use of inhaled heparin/N-acetylcystine in
inhalation injury: does it help? J Burn Care Res. 2008;29(1):192–5.
118. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized
unfractionated heparin and N-acetylcysteine in acute lung injury after
smoke inhalation injury. J Burn Care Res. 2009;30(2):249–56.
119. Yip LY, Lim YF, Chan HN. Safety and potential anticoagulant effects of
nebulised heparin in burns patients with inhalational injury at Singapore
General Hospital Burns Centre. Burns. 2011;37(7):1154–60.
120. Kashefi NS, Nathan JI, Dissanaike S. Does a nebulized heparin/N-
acetylcysteine protocol improve outcomes in adult smoke inhalation? Plast
Reconstr Surg Glob Open. 2014;2(6):e165.
121. McIntire AM, Harris SA, Whitten JA, Fritschle-Hilliard AC, Foster DR, Sood R,
Walroth TA. Outcomes following the use of nebulized heparin for inhalation
injury (HIHI study). J Burn Care Res. 2017;38(1):45–52.
122. Glas GJ, Muller J, Binnekade JM, Cleffken B, Colpaert K, Dixon B, Juffermans
NP, Knape P, Levi MM, Loef BG, Mackie DP, Malbrain M, Schultz MJ, van der
Sluijs KF. HEPBURN - investigating the efficacy and safety of nebulized
heparin versus placebo in burn patients with inhalation trauma: study
protocol for a multi-center randomized controlled trial. Trials. 2014;15:91.
123. Dixon B, Smith R, Artigas A, Laffey J, McNicholas B, Schmidt E, Nunes Q,
Skidmore M, Andrade de Lome M, Moran J, van Haren F, Doig G, Gupta S,
Ghosh A, Said S, Santamaria J. Can nebulised heparin reduce time to
extubation in SARS CoV 2 the CHARTER Study protocol. medRxiv. 2020.
https://doi.org/10.1101/2020.04.28.20082552.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
van Haren et al. Critical Care          (2020) 24:454 Page 11 of 11
